Candel Therapeutics, Inc. (CADL): Price-to-Projected Revenue Ratio

candeltx.com (CADL) - corporate logo

Risks for Candel Therapeutics (CADL) are limited solely to formal compliance with environmental regulations and reagent disposal. The issuer's forward P/S visualizes these aspects, where the 1523.70 mark indicates the current state. Stability is ensured by the patent protection of viral platforms and regulatory complexity. Growth potential is based on inelastic demand for unique metastasis destruction methods, which guarantees high pricing power for Candel Therapeutics (CADL).

Candel Therapeutics, Inc. - CADL Market Cap to Projected Revenue (period 07/04/2022 - 03/29/2024)

candeltx.com (CADL) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Candel Therapeutics, Inc.|CADL - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Candel Therapeutics, Inc.|CADL - Business Value
- book value of equity indicators:
Book Value per Share Candel Therapeutics|CADL - Accounting Capitalization|Market Capitalization to Book Value Ratio candeltx.com|CADL - Company Assets
- company total debt and liquidity indicators:
Debt to Equity Candel Therapeutics|CADL - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Candel Therapeutics, Inc.|CADL - Aggregate Debt Obligations|Debt to Book Value Candel Therapeutics, Inc.|CADL - Amount of Long-Term Liabilities|Company Short-Term Debts Candel Therapeutics|Quick Ratio candeltx.com
- financial results and valuation multiples details:
CADL - Company Net Income|Expected Profit Candel Therapeutics|CADL - Company Value to Net Income|Forward P/E Multiple Candel Therapeutics, Inc.|CADL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Candel Therapeutics, Inc.|CADL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Candel Therapeutics|CADL - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months candeltx.com|CADL - Earnings growth in current year|Expected earnings per share growth for next year Candel Therapeutics
- sales and revenue indicators:
CADL - Company Total Sales|Projected Sales Volume Candel Therapeutics, Inc.|CADL - Price-to-Revenue Coefficient|Forward P/S Multiple Candel Therapeutics, Inc.
Summary company analysis:Candel (CADL)
Original product of Candel Therapeutics Inc.

Screening market value relative to projected revenue is critical for constructing a defensive portfolio within the biopharmaceutical sector. This metric correlates the capitalization of Candel Therapeutics (CADL) with expected sales, determining the degree of asset overvaluation within a drug development cycle that remains independent of macroeconomic trends. Analyzing the expected P/S chart for Candel Therapeutics (CADL) allows for an assessment of whether current quotes are fair relative to the business's fundamental prospects.

Competing companies

Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD - Price-to-Projected Revenue Ratio|AAPG (Ascentage Pharma Corp) - Market Cap to Projected Revenue|CGON: Forward P/S Multiple|Market Cap to Projected Revenue URGN|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Personalis Inc PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Price-to-Projected Revenue Ratio DCTH (Delcath Corp)|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales AURA|ARAY: Forward Price-to-Revenue Multiple|SELLAS Life Sciences - Price to Expected Revenue Ratio|ACTU: Forward P/S Multiple|Citius Oncology Inc - Forward Price to Sales|HURA (TuHURA Biosciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio protaratx.com TARA|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|WHWK (aadibio.com) - Forward Price to Sales|Forward P/S Multiple TCRX (TScan Therapeutics, Inc.)|Forward P/S Multiple Champions Oncology Inc CSBR|XBIT - Price-to-Projected Revenue Ratio|Future Price to Revenue CVM|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio radiopharmtheranostics.com (RADX)|Forward Price-to-Revenue Multiple ARTV|Forward P/S Multiple Adlai Nortye Limited|Forward Price-to-Revenue Multiple VERU (Veru Inc.)|Price to Expected Revenue Ratio TPST|Forward P/S Multiple XLO (Xilio Therapeutics)|Market Cap to Expected Sales Ratio Renovaro Biosciences (RENB)|Mural Bio - Forward P/S Multiple|Kairos Pharma Ltd (KAPA) - Forward Price-to-Revenue Multiple|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|GDTC - Market Cap to Expected Sales Ratio|CRIS (Curis Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Apollomics Corp (APLM)|Forward P/S Multiple THAR|Forward P/S Multiple advanbiomed.com (ADVB)|Forward P/S Multiple GNPX (Genprex, Inc.)|CLDI: Market Cap to Projected Revenue|SBFM - Price-to-Projected Revenue Ratio|XBIO: Price-to-Projected Revenue Ratio|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward P/S Multiple beigene.com|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Market Cap to Projected Revenue|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viracta Therapeutics|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|Forward Price-to-Revenue Multiple AAPGV